# A Phase I Dose Finding Study of MB-CART2219.1

> **NCT07108868** · PHASE1 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 36 (estimated)

## Conditions studied

- Lymphoma
- CLL
- Acute Lymphoblastic Leukemia, Pediatric

## Interventions

- **BIOLOGICAL:** CAR-T cells targeting CD19 and CD22

## Key facts

- **NCT ID:** NCT07108868
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-03
- **Final completion:** 2027-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108868, "A Phase I Dose Finding Study of MB-CART2219.1". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07108868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*